middle.news
How Echo IQ’s EchoSolv HF Could Revolutionise US Heart Failure Diagnosis
12:32pm on Friday 23rd of January, 2026 AEDT
•
Healthcare
Read Story
How Echo IQ’s EchoSolv HF Could Revolutionise US Heart Failure Diagnosis
12:32pm on Friday 23rd of January, 2026 AEDT
Key Points
EchoSolv HF validated with 99.5% sensitivity and 91.0% specificity by Mayo Clinic Platform
Formal FDA 510(k) submission lodged in December 2025, clearance expected soon
US heart failure market opportunity estimated at US$60 billion
EchoSolv AS platform adoption progressing through beta testing and partnerships
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Echoiq (ASX:EIQ)
OPEN ARTICLE